寄生菌
医学
孕激素
药代动力学
炔雌醇
药效学
雌激素
药理学
药品
激素避孕
激素
安全概况
人口
左炔诺孕酮
临床研究
内科学
药丸
突破性出血
临床试验
生理学
计划生育
临床药理学
临床疗效
三氨甲苯
血浆浓度
子宫内膜异位症
妇科
不利影响
雄激素
作者
Marta Barretta,Jacques B.E. Versailles,Luís Bahamondes,Cassia Teatin Juliato,Giovanni Grandi
标识
DOI:10.1080/17425255.2026.2764080
摘要
INTRODUCTION: Combined oral contraceptives (COCs) have traditionally evolved through changes in estrogen and progestin type and dose. More recently, drug-delivery technology has emerged as an additional strategy to modify pharmacokinetic (PK) profiles without altering hormonal components. AREAS COVERED: A structured search of MEDLINE and regulatory sources was conducted to review the PK and pharmacodynamic characteristics of a prolonged-release COC containing dienogest (DNG) 2 mg and ethinylestradiol (EE) 0.02 mg, and to explore their clinical implications. Compared with immediate-release formulations, prolonged-release DNG/EE produces delayed peak concentrations, lower plasma peak levels, and reduced intra-day hormonal fluctuations while maintaining comparable overall exposure. EXPERT OPINION: Clinical evidence indicates contraceptive efficacy comparable to other COCs, with improved bleeding control compared with an immediate-release formulation. Both the intrinsic endometrial effects of DNG and more stable hormonal exposure may contribute . The formulation also provides antiandrogenic effects that may benefit hirsutism in women with PCOS. The safety profile appears broadly consistent with other low-dose COCs, although the effect on thromboembolic risk remains uncertain. Prolonged-release technology adds a new dimension to contraceptive choice. Further comparative and post-marketing studies are needed to establish its clinical advantages and long-term safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI